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The HLA-DRB1*15:01-DQA1*01:02-DQB1*06:02 haplotype
is linked to protection from the development of type 1
diabetes (T1D). However, it is not known at which stages
in the natural history of T1D development this haplotype
affords protection. We examined a cohort of 3,358 auto-
antibody-positive relatives of T1D patients in the Pathway
to Prevention (PTP) Study of the Type 1 Diabetes TrialNet.
The PTP study examines risk factors for T1D and disease
progression in relatives. HLA typing revealed that 155
relatives carried this protective haplotype. A compari-
son with 60 autoantibody-negative relatives suggested
protection from autoantibody development. Moreover,
the relatives with DRB1*15:01-DQA1*01:02-DQB1*06:02
less frequently expressed autoantibodies associated with
higher T1D risk, were less likely to have multiple autoan-
tibodies at baseline, and rarely converted from single to
multiple autoantibody positivity on follow-up. These rela-
tives also had lower frequencies of metabolic abnorm-
alities at baseline and exhibited no overall metabolic
worsening on follow-up. Ultimately, they had a very low
5-year cumulative incidence of T1D. In conclusion, the pro-
tective influence of DRB1*15:01-DQA1*01:02-DQB1*06:02
spans from autoantibody development through all stages
of progression, and relatives with this allele only rarely de-
velop T1D.
HLAs are antigen-presenting molecules that play a key
role in mediating adaptive immune responses. HLA class I
and class II molecules are restricting elements for CD8
and CD4 T-cell responses, respectively. They are encoded
by polymorphic genes in the HLA complex, and a number
of HLA gene variants have been linked to immune-mediated
and autoimmune diseases (1,2). In type 1 diabetes (T1D),
certain HLA class I and class II variants increase disease
risk; these include the class I molecules encoded by A*02:01,
A*24, and B39 and the class II molecules encoded by the
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DRB1*04 (DR4)-DQA1*03:01-DQB1*03:02 and DRB1*03:01
(DR3)-DQA1*05:01-DQB1:02:01 haplotypes. In T1D, HLA-
encoded susceptibility confers up to 50–60% of the overall
genetic risk from inherited alleles (3).
Other HLA variants are linked to genetic protection
from T1D. Among four HLA-DR2 (DRB1*15) haplotypes
observed in Caucasians, the DRB1*15:01-DQA1*01:02-
DQB1*06:02 haplotype is commonly found in Caucasians
and is negatively associated with T1D (4–8). Individuals
with this haplotype are extremely rare (,1%) in most
T1D populations studied (9,10). The disease association
of various HLA-DR2 haplotypes expressing diverse link-
age patterns of DRB1 and DQA1/DQB1 alleles (5,10–13)
or unusual DQA1/DQB1 alleles in cis with the usual
DRB1*15:01 allele (14,15) suggests that protection from
T1D maps largely to the DQA1*01:02 and DQB1*06:02
alleles, which together encode for the HLA-DQ6 hete-
rodimer. DRB1*15:01-DQA1*01:02-DQB1*06:02 has been
previously linked to protection from T1D development
among first-degree relatives with autoantibodies to islet
cell autoantigens (7,16–19). This suggests that genetic
protection may not always prevent the triggering of is-
let autoimmunity in relatives; yet, they rarely develop
diabetes.
Nevertheless, it is not known at which stages during
the natural history of T1D development that this haplo-
type is protective, including the initial triggering of auto-
antibodies, the development of multiple autoantibody
responses to islet antigens, and the occurrence of metabolic
changes indicating b-cell function deterioration eventually
leading to clinically manifest diabetes. Such knowledge is of
potential importance, as it could yield insights for devising
preventive strategies against the disease. To this end, we
examined the Pathway to Prevention (PTP) cohort of the
Type 1 Diabetes TrialNet (TrialNet), a consortium of in-
vestigators studying the natural history, risk factors, and
prevention of T1D (20). The cohort includes over 3,000
relatives of T1D patients who were found to express
T1D-associated autoantibodies and are followed long-
itudinally with repeat oral glucose tolerance and auto-
antibody testing until the development of T1D. This is
the first study to examine the protective influence of
DRB1*15:01-DQA1*01:02-DQB1*06:02 throughout the
progression to T1D.
RESEARCH DESIGN AND METHODS
Subjects
These analyses include 3,358 relatives (first to third degree)
of patients with T1D who expressed T1D-associated au-
toantibodies and therefore are at increased risk for disease
development. The relatives were identified by TrialNet, a
National Institutes of Health–sponsored consortium that
conducts clinical research studies in T1D patients and their
relatives, including prevention trials and intervention trials
following T1D diagnosis. As a control group for these PTP
relatives, 60 autoantibody-negative relatives were studied;
the TrialNet Coordinating Center generated randomized
lists of autoantibody-negative PTP participants, which
were then provided to TrialNet Clinical Centers for recruit-
ment. All subjects signed informed consent and the study
was approved by the ethics boards of all participating insti-
tutions. Demographic characteristics are shown in Table 1.
Participants self-reported race and ethnicity in the screen-
ing form.
Table 1—Characteristics of PTP participants by autoantibody status
AAb+ (n = 3,358) AAb2 (n = 60) P
Age (years) 18.2 6 13.4 (n = 3,325) 16.6 6 10.1 (n = 60) 0.23
BMI (kg/m2) 21.7 6 6.7 (n = 3,222) 20.7 6 5.3 (n = 57) 0.15
Sex (% female) 53.2 52.5 0.91
Relation to the proband
0.60*Offspring 18.5 (n = 613) 18.6 (n = 11)
Parent 21.2 (n = 705) 15.2 (n = 9)
Sibling 52.0 (n = 1,726) 52.5 (n = 31)
Other 8.3 (n = 276) 13.5 (n = 8)
Unknown (n = 38) (n = 1)
Duration of follow-up (years) 3.0 6 2.3 4.5 6 1.7 ,0.0001
Race
0.04**White 87.1 (n = 2,872) 96.4 (n = 53)
Other 12.9 (n = 424) 3.6 (n = 2)
Unknown (n = 62) (n = 5)
Ethnicity
0.05*Hispanic or Latino 12.3 (n = 394) 3.6 (n = 2)
Not Hispanic or Latino 87.7 (n = 2,806) 96.4 (n = 54)
Other (n = 107) (n = 1)
Unknown (n = 51) (n = 3)
Data are mean 6 SD or %. AAb, autoantibody. *The comparison does not include “other” and “unknown.” **The comparison does not
include “unknown.”
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Study Design
The TrialNet PTP Study, formerly known as the Natural
History Study, screens relatives of T1D patients for the
presence of islet autoantibodies (20). Between 2000 and
30 September 2014, TrialNet screened approximately
140,000 relatives of patients with T1D for T1D-associated
autoantibodies to glutamic acid decarboxylase 65 (GAD65A),
tyrosine phosphatase-like insulinoma-associated protein
(IA-2A), and insulin (mIAA). Relatives positive for any
of these autoantibodies were subsequently tested for
islet cell antibodies, and a subset were also tested for
autoantibodies to the zinc transporter 8 (ZnT8A), as
described below. Initially, all those with at least one auto-
antibody were prospectively followed with testing every 6
months for autoantibodies and metabolic evaluation by
oral glucose tolerance test (OGTT). After 2012, some par-
ticipants with single autoantibodies, who are considered at
lower risk, have been followed at yearly intervals. The
autoantibody-negative relatives had the same baseline testing
as those who were autoantibody positive; they have been
followed with autoantibody and OGTT measurements at
yearly intervals. For the OGTTs, samples for plasma
glucose and C-peptide measurement were obtained in the
fasting state and at 30, 60, 90, and 120 min after ingestion
of a 1.75 g per kilogram glucose dose (maximum: 75 g of
carbohydrate). Dysglycemia was defined by a fasting glu-
cose value $110 mg/dL, a 2-h value of 140–199 mg/dL,
and/or a 30-, 60-, 90-min glucose value $200 mg/dL. The
diagnosis of T1D was made according to American Diabetes
Association guidelines. This required either two consecutive
OGTTs in which fasting glucose values were $126 mg/dL
and/or 2-h glucose values $200 mg/dL and/or HbA1c
$6.5% and/or clinical symptoms associated with random
glucose $200 mg/dL (21). An OGTT was repeated for
diagnostic confirmation if the fasting glucose value
was $126 mg/dL and/or the 2-h glucose value was
$200 mg/dL. If both thresholds were not exceeded on
the confirmatory OGTT, participants were followed as be-
fore. We calculated the progression scale at 6 months
(PS6M), which is a measure of change in the glucose sum
(from the 30-, 60-, 90-, and 120-min values of OGTTs) over
a 6-month period (22). Autoantibody-positive individuals
who do not progress to T1D with at least 2 years of follow-
up (nonprogressors) are expected to have an average PS6M
value of zero. We also evaluated early C-peptide secretion
during OGTTs as defined by the 30 2 0 min difference
in C-peptide levels. This measure correlates highly with
the first-phase insulin response of an intravenous glucose
tolerance test (23).
Laboratory Procedures
All autoantibodies were measured using standardized
radioimmunoassays (24,25). Screening identified 3,358
relatives expressing at least one autoantibody. Following
discovery of the ZnT8 autoantigen in 2007 (26) and the
development of a specific radioimmunoassay, a subset of
1,940 autoantibody-positive relatives was tested for ZnT8A.
Samples that were positive for mIAA and/or GADA were
also tested with the new electrochemiluminescence (ECL)
assays (ECL-IAA and ECL-GADA, respectively) at the Bar-
bara Davis Center Autoantibody/HLA Core Laboratory, as
previously described (27–29). Both the ECL-IAA and ECL-
GADA identify autoantibody responses that are more dis-
ease specific and are stronger predictors of T1D risk than
the standard radioimmunoassays. ECL results were avail-
able from 931 autoantibody-positive relatives; of whom,
346 had multiple autoantibodies and 243 had T1D. Rela-
tives were typed for HLA class II DRB1, DQA1, and DQB1
alleles using DNA-based typing with oligonucleotide probes,
as previously reported (30). C-peptide levels were measured
by an immunoenzymometric assay using the Tosoh
AIA-600II autoanalyzer (Tosoh Bioscience, South San
Francisco, CA) (31). The glucose oxidase method was used
to measure the plasma glucose.
Data Analysis
The x2 tests and t tests were used to compare groups. Paired
t tests were used to assess changes over time (at the
beginning and end of follow-up). Cumulative incidence
was determined by Kaplan-Meier analysis. Log-rank test-
ing was used to compare cumulative incidence. Proportional
hazards regression was used to assess time-dependent asso-
ciations. 95% CIs are included with estimates of risk. Ad-
justments for multiple comparisons were not performed.
RESULTS
Characteristics at Baseline
In the PTP study, 3,358 PTP study participants were au-
toantibody positive and HLA typed for class II DRB1,
DQA1, and DQB1 alleles. A group of 60 autoantibody-
negative relatives were also typed. Key baseline character-
istics are shown in Table 1 for both autoantibody-positive
and autoantibody-negative relatives. Baseline characte-
ristics for the autoantibody-positive relatives, according
to the absence or presence of DRB1*15:01-DQA1*01:02-
DQB1*06:02, are shown in Table 2; from here onward, we
will refer to the two categories of autoantibody-positive
relatives as 0602+ and 06022, respectively. The 0602+
group had a higher mean age (P , 0.0001) with higher
BMI values (P , 0.0001); sex was not significantly differ-
ent. The 0602+ relatives more frequently included parents
and less frequently included siblings of T1D probands
(P = 0.01) (Table 2). The 60 autoantibody-negative rela-
tives were similar in age, BMI, and sex to the autoantibody-
positive relatives (Table 1); .85% of the relatives were
white and not Hispanic in all the groups compared.
Frequency of DRB1*15:01-DQA1*01:02-DQB1*06:02
The frequency of DRB1*15:01-DQA1*01:02-DQB1*06:02
was higher among autoantibody-negative than that among
autoantibody-positive relatives [10/60 (17%) vs. 155/3,358
(4.6%)]; the odds ratio (OR) was highly significant, consis-
tent with protection from autoantibody development by
DRB1*15:01-DQA1*01:02-DQB1*06:02 positivity (OR 0.242
[95% CI 0.120, 0.486], P , 0.001).
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Frequencies of Autoantibody Positivity at Baseline
Table 3 compares baseline GADA, IA-2A, and mIAA auto-
antibody patterns between 0602+ and 06022 participants.
The 0602+ relatives had lower proportions of autoantibody
positivity for all autoantibodies: GADA (72.9% vs. 80.4%,
P = 0.02), IA-2A (17.4% vs. 35.5%, P , 0.0001), and mIAA
(29.7% vs. 38.2%, P = 0.03). The 0602+ relatives had
a higher proportion of single autoantibodies (84.5% vs.
59.0%, P , 0.0001), most commonly GADA, and lower
proportions of multiple autoantibodies (two autoantibodies,
11.0% vs. 27.9%, P, 0.0001; three autoantibodies, 4.5% vs.
13.0%, P , 0.0001). These findings were mirrored in the
smaller subset with available ZnT8A measurements (n =
1,940); 0602+ relatives less frequently expressed ZnT8A
(12.9% vs. 36.1%, P , 0.0001) and four autoantibodies
(5.9% vs. 10.5%, P , 0.0001).
When GADA and mIAA were measured by ECL assays,
ECL positivity was associated with increased risk (27,28);
the proportions with ECL positivity were lower in 0602+
relatives than in 06022 relatives for GADA (21/47 [44.7%]
vs. 550/883 [62.3%], P = 0.02] and mIAA (5/47 [11.6%] vs.
305/884 [34.8%], P , 0.001).
Progression to Multiple Autoantibodies
Figure 1A compares cumulative incidence curves between
the 0602+ and 06022 relatives for progression from one
to two or more autoantibodies in the entire data set (not
including ZnT8A). The progression to multiple autoanti-
bodies was lower (log-rank test, P = 0.001) in 0602+ rela-
tives. The 5-year conversion estimates (95% CI) for 0602+
and 06022 relatives were 19.0% (11, 31.5) and 33% (30.4,
36.7), respectively. The hazard ratio (HR) was 0.42 (0.25,
0.72). Overall, 14/131 (10.7%) 0602+ relatives and 413/
1,890 (21.8%) 06022 relatives converted from single to
multiple autoantibody positivity on follow-up (P = 0.003,
OR 0.43 [95% CI 0.24, 0.75]). Data are also shown for
siblings only (Fig. 1B) (log-rank test, P = 0.0135): the
5-year conversion estimates (95% CI) for 0602+ and
06022 relatives were 20.0% (9.8, 38.4) and 44% (38.7,
49.2), respectively. The HR was 0.40 (0.19, 0.85). Overall,
7/48 (14.6%) 0602+ relatives and 239/831 (28.8%) 06022
relatives converted from single to multiple autoantibody
Table 2—Characteristics of PTP participants by DRB1*15:01-DQA1*01:02-DQB1*06:02 status
0602+ (n = 155) 06022 (n = 3,203) P
Age (years) 23.7 6 14.5 (n = 154) 17.9 6 13.3 (n = 3,171) ,0.0001
BMI (kg/m2)* 23.9 6 7.1 21.6 6 6.6 ,0.0001
Sex (% female) 59.1 53.0 0.14
Relation to the proband
0.01*Offspring 16.9 (n = 26) 18.5 (n = 587)
Parent 31.1 (n = 48) 20.8 (n = 657)
Sibling 42.9 (n = 66) 52.4 (n = 1,660)
Other 9.1 (n = 14) 8.3 (n = 262)
Unknown (n = 1) (n = 37)
Duration of follow-up (years) 3.5 6 2.2 3.0 6 2.3 0.01
Race
0.35**White 89.6 (n = 138) 87.0 (n = 2,734)
Other 10.4 (n = 16) 13.0 (n = 408)
Unknown (n = 1) (n = 61)
Ethnicity
0.17*Hispanic or Latino 8.7 (n = 13) 12.5 (n = 381)
Not Hispanic or Latino 91.3 (n = 136) 87.5 (n = 2,670)
Other (n = 4) (n = 103)
Unknown (n = 2) (n = 49)
Data are mean 6 SD or %. *The comparison does not include “other” and “unknown.” **The comparison does not include “unknown.”
Table 3—Frequency of autoantibody positivity in 0602+ and
06022 relatives at screening
0602+ (n = 155) 06022 (n = 3,203) P
Entire data set
(n = 3,203)
GAD65A 72.9 (113/155) 80.4 (2,574/3,203) 0.02
IA-2A 17.4 (27/155) 35.5 (1,136/3,203) ,0.0001
mIAA 29.7 (46/155) 38.2 (1,124/3,203) 0.03
1 AAb 84.5 (131/155) 59.0 (1,890/3,203) ,0.0001
2 AAb 11.0 (17/155) 27.9 (895/3,203) ,0.0001
3 AAb 4.5 (7/155) 13.0 (418/3,203) ,0.0001
0602+ (n = 85) 06022 (n = 1,855) P
Subset tested for ZnT8A
(n = 1,940)
GAD65A 78.2 (67/85) 80.2 (1,488/1,855) 0.75
IA-2A 18.8 (16/85) 36.1 (670/1,855) 0.001
mIAA 24.7 (21/85) 39.0 (723/1,855) 0.008
ZnT8A 12.9 (11/85) 36.1 (669/1,855) ,0.0001
1 AAb 81.2 (69/85) 48.3 (896/1,855) ,0.0001
2 AAb 8.2 (7/85) 22.5 (418/1,855) ,0.0001
3 AAb 4.7 (4/85) 18.6 (346/1,855) ,0.0001
4 AAb 5.9 (5/85) 10.5 (195/1,855) ,0.0001
Data are % (n/N ), unless stated otherwise. AAb, autoantibody.
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positivity on follow-up (P = 0.03, OR 0.42 [95% CI 0.19,
0.96]). Both HRs and ORs indicate strong protection by
DRB1*15:01-DQA1*01:02-DQB1*06:02 positivity from the
development of multiple autoantibodies.
Metabolic Measures at Baseline
Table 4 compares frequencies of abnormal glucose toler-
ance at baseline between 0602+ and 06022 relatives with
autoantibodies for those relatives who had data for all OGTT
time points. The 0602+ relatives had a lower frequency of
diabetic range values (fasting glucose values $126 mg/dL
and/or 2-h glucose values $200 mg/dL) in their baseline
OGTTs (P = 0.004). Among autoantibody-positive rela-
tives whose glucose values were in the nondiabetic range,
0602+ relatives also had a lower frequency of dysglyce-
mic OGTTs (P = 0.013). The sum of glucose (glucose
sum) values from 30 to 120 min was also lower in those
individuals (509 6 90 mg/dL vs. 530 6 109 mg/dL, P =
0.008; data not shown).
In 0602+ relatives, the proportion with an impaired
early C-peptide response (as defined by 302 0 min C-peptide
difference values ,2.0 ng/mL), which correlates with the
first-phase insulin response (23), was significantly lower
than in 06022 relatives [10/150 (6.6%) vs. 723/3,071
(23.5%), P , 0.001; data not shown). The Diabetes Pre-
vention Trial-Type 1 (DPT-1) Risk Score (DPTRS) (32),
which is based on glucose and C-peptide measures along
with age and BMI, was also lower in 0602+ relatives
(5.5 6 1.1 vs. 6.1 6 1.3, P , 0.001; data not shown).
Changes in Glycemia From Baseline
The change in glucose concentrations from baseline to the
6-month visit, as indicated by the PS6M, was lower in
0602+ relatives (2.3 6 77.2 ng/mL [n = 75] vs. 25.9 6
101.9 ng/mL [n = 1,341], P = 0.01]. Table 5 shows OGTT
glucose values at baseline and at the 24-month (6 3 months)
visit in 0602+ and 06022 relatives. The 06022 relatives
showed a statistically significant increase at all OGTT time
points and in the glucose sum over the 24 months; in
contrast, there were no significant changes for 0602+
relatives. Moreover, 0602+ relatives showed a slight de-
crease in the glucose sum values from baseline, whereas
there was an appreciable increase in the 06022 relatives
(P , 0.001).
Diagnosis of T1D
The cumulative incidence for T1D (Fig. 2A) was much
lower for 0602+ relatives (P , 0.0001). The 5-year T1D
incidence estimates for 0602+ and 06022 relatives were
3.8% (95% CI 1.3, 10.5) and 28.5% (26.4, 30.8), respec-
tively. The HR (95% CI) for the presence of 0602 was 0.11
(0.04, 0.29), indicating a strong protective effect of
DRB1*15:01-DQA1*01:02-DQB1*06:02 positivity. Among
those with dysglycemia at baseline (Fig. 2B), progression
to T1D occurred less frequently in the 0602+ relatives
(2/21 [9.5%] vs. 204/664 [30.7%]) (HR 0.24 [0.05, 1.03],
P = 0.05). When we analyzed relatives with higher risk be-
cause of the presence of HLA-DR3 or -DR4 and multiple
autoantibodies, protection was still evident: only 17.6%
(3/17) of the 0602+ relatives have progressed to T1D
Table 4—Proportions of 0602+ and 06022 relatives with abnormal glucose tolerance at baseline OGTT
0602+ 06022 OR (95% CI) P
Diabetes 2/155 (1.3) 219/3,203 (6.8) 0.13 (0.03, 0.79) 0.004
Dysglycemic 21/143 (14.7) 664/2,781 (23.8) 0.55 (0.34, 0.88) 0.013
Data are n/N (%), unless stated otherwise.
Figure 1—Cumulative incidence of conversion from single to mul-
tiple autoantibodies in 0602+ and 06022 relatives. A: Entire data set.
B: Siblings only.
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compared with 34.1% (548/832, P , 0.0001) of 06022
relatives. However, only 1/131 (0.8%) 0602+ relatives
with a single autoantibody developed T1D compared with
the 3/17 (17.6%) 0602+ relatives with multiple autoan-
tibodies (P , 0.0001). Overall, only 4 of the 155 0602+
relatives developed diabetes on follow-up. The character-
istics of the 0602+ individuals diagnosed with diabetes
are shown in Table 6. One of the four relatives was 44.7
years of age at diagnosis and positive only for GADA.
The others were all less than 16 years of age at diagnosis
and had at least two autoantibodies; two subjects had
high BMI values.
Frequency of Predisposing HLA Haplotypes
We investigated whether the presence of autoantibodies
and the reduced incidence of T1D in 0602+ relatives were
related to a potential lack of HLA predisposition on the
other chromosome. We present data for all such relatives,
and then for those with a single autoantibody at screening
and on follow-up, those who acquired multiple autoanti-
bodies on follow-up, and those who already had multiple
autoantibodies at screening (Table 7). We determined the
frequencies of HLA-DR3 and -DR4 haplotypes, also ac-
counting for the contribution of the DQ locus in 0602+
and 06022 relatives. Considering that in the 0602+ group
one chromosome is fixed, we compared the frequency of
DR3 or DR4 haplotypes alone, so that the frequency is in-
dependent of the other chromosome. Specifically, we com-
pared the frequency of
1. DR3, meaning any DR3 haplotype (DRB1*03) without
DR4 (any DR4, DRB1*04), and more specifically the
T1D-associated DR3 haplotype (DRB1*03:01-DQA1*05:01-
DQB1*02:01) without any DR4; overall, 8 (0.3%) DR3-
positive subjects did not have the T1D-associated DR3.
2. DR4, meaning any DR4 haplotype (DRB1*04) without
DR3 (any DR3, DRB1*03), and more specifically the T1D-
associated DR4 haplotypes bearing HLA-DQ8 (DRB1*04-
DQA1*03:01-DQB1*03:02) without DR3; overall, 212
(8.1%) of the DR4-positive subjects did not have T1D-
associated DR4-DQ8 haplotypes. Although not directly
compared in the Table 7, this frequency did not differ
among 0602+ and 06022 relatives (for all the groups
compared P = 0.5–0.9).
3. DR3/DR4 heterozygous genotypes, any DR3 haplotype
(DRB1*03) together with any DR4 haplotype (DRB1*04),
and then T1D-associated genotypes encoded by DRB1*04-
DQA1*03:01-DQB1*03:02 together with DRB1*03:01-
DQA1*05:01-DQB1*02:01.
Table 5—Glucose values (mg/dL) at baseline and 24 months in 0602+ and 06022 relatives
0602+ (n = 50) 06022 (n = 671)
Baseline 24 months P Baseline 24 months P
0 min 88 6 6 89 6 8 n.s. 89 6 9 91 6 11 ,0.01
30 min 135 6 21 138 6 23 n.s. 144 6 28 146 6 30 ,0.05
60 min 134 6 31 135 6 33 n.s. 140 6 36 148 6 44 ,0.001
90 min 121 6 27 117 6 31 n.s. 125 6 34 133 6 47 ,0.001
120 min 111 6 27 105 6 25 n.s. 117 6 27 124 6 45 ,0.001
Glucose sum 500 6 83 495 6 90 n.s. 526 6 104 551 6 146 ,0.001
Data are mean 6 SD, unless stated otherwise. n.s., not significant.
Figure 2—Cumulative incidence of T1D in 0602+ and 06022 rela-
tives. A: Entire data set. B: Subset of relatives with dysglycemia at
baseline.
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The comparisons predictably show that there were dif-
ferences in the frequency of DR3/DR4 genotypes among
0602+ and 06022 relatives in all subsets compared,
which are explained by the fact that 0602+ relatives can-
not have this genotype. There were no statistically signif-
icant differences for DR3 haplotypes in any comparison.
However, the frequency of DRB1*04 haplotypes, with and
without DQA1*03:01-DQB1*03:02, was lower among 0602+
relatives in comparisons of all autoantibody-positive
relatives and of relatives with a single autoantibody at
screening and on follow-up. Such differences in DR4 hap-
lotypes were not observed in comparisons of relatives
who multiple autoantibodies acquired on follow-up and of
relatives who had multiple autoantibodies at screening.
We then compared the frequency of DRB1*04-
DQA1*03:01-DQB1*03:02 (alone) in 0602+ and 06022
relatives with multiple autoantibodies (either at screening
or on follow-up) and found that only 1/16 (6.2%) of the
0602+ relatives had T1D compared with 220/691 (31.8%)
of 06022 relatives (P = 0.02, OR 0.14, Fisher exact test).
None of the 0602+ relatives with a single autoantibody and
DRB1*04-DQA1*03:01-DQB1*03:02 had developed T1D.
Finally, we compared the occurrence of T1D, multiple
autoantibodies, positivity for each autoantibody, and dys-
glycemia at baseline and at the end of the follow-up for
0602+ relatives according to the presence of DR3 or
DR4-DQ8 (DR4B1*04-DQA1*03:01-DQB1*03:02) on the
other chromosome. The above parameters did not differ
in this comparison, except that relatives that were 0602+
and DR4-DQ8+ were more frequently positive for multiple
autoantibodies (16/45, 35.6%) than those carrying DR3
(9/54, 16.7%; P = 0.0382) (Supplementary Table 1).
DISCUSSION
Prior studies of islet autoantibody-positive relatives showed
that those carrying the protective DRB1*15:01-DQA1*01:02-
DQB1*06:02 haplotype have a very low risk of developing
T1D; such relatives are unlikely to express multiple auto-
antibodies (7,16–19). In addition, in most 0602+ relatives,
T1D did not develop even in the presence of HLA alleles
that confer susceptibility on the other chromosome. However,
prior studies have not examined the effect of DRB1*15:01-
DQA1*01:02-DQB1*06:02 throughout the natural history of
islet autoimmunity.
Previous studies have not compared the frequency of
DRB1*15:01-DQA1*01:02-DQB1*06:02 between autoantibody-
positive and autoantibody-negative relatives. Our cross-
sectional analysis indicates that autoantibody-negative
relatives carry DRB1*15:01-DQA1*01:02-DQB1*06:02 at
similar frequency to that of Caucasian populations (www
.allelefrequencies.net) but higher compared with autoanti-
body-positive relatives; moreover, we show that autoanti-
body development is less likely in 0602+ relatives, a finding
that will require confirmation in prospective studies of
autoantibody-negative relatives.
Among autoantibody-positive relatives, we show that
those with DRB1*15:01-DQA1*01:02-DQB1*06:02 are less
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frequently positive for each autoantibody studied, includ-
ing ZnT8A, which was not included in earlier reports. The
most prevalent autoantibody among 0602+ relatives was
GADA, most often as a single autoantibody, which implies
a lower risk of future T1D among autoantibody-positive
relatives (33–36). The 0602+ relatives much less frequently
expressed IA-2A, ZnT8A, and multiple autoantibodies,
markers of more advanced islet autoimmunity and more
rapid disease progression that typically appear closer to
diagnosis.
In addition, our study is the first to show that 0602+
relatives were less often positive for GADA and IAA
measured by ECL assays, which identify autoantibody
responses more strongly associated with progression
(27,28). Although others have observed lower propor-
tions of multiple autoantibodies in 0602+ individuals,
we provide the first prospective data showing decreased
progression from single to multiple autoantibodies in
0602+ relatives.
The metabolic data also showed evidence of protection
by the DRB1*15:01-DQA1*01:02-DQB1*06:02 allele. Both
diabetic range and dysglycemic OGTTs were less common
at baseline in the 0602+ relatives. In addition, the fre-
quency of an impaired early C-peptide response was also
lower at baseline in 0602+ relatives, indicating better
b-cell function. The longitudinal assessments of changes
in glycemia were consistent with a protective effect of
DRB1*15:01-DQA1*01:02-DQB1*06:02. Average PS6M val-
ues approached zero, the value expected for nonprogres-
sors, over a 6-month period. In contrast to 06022 relatives,
0602+ relatives showed essentially no change in glycemia
over a 24-month period. Even among those with dysgly-
cemia, fewer progressed to T1D.
Our study also shows that 0602+ relatives less
frequently bear DR4 haplotypes, including those carrying
the high-risk DQA1*03:01-DQB1*03:02 allele. Further
analysis by autoantibody status reveals that this differ-
ence is true for relatives with a single autoantibody,
whereas the frequency of DR4 haplotypes among relatives
with multiple autoantibodies is similar among 0602+ and
06022 relatives. This suggests that the presence of DR4
among 0602+ relatives is associated with multiple auto-
antibodies; consistent with this, 0602+ relatives with
DR4-DQ8 are more likely to have multiple autoantibodies
than 0602+ relatives with DR3. However, the risk of
T1D was much lower in 0602+ relatives with multiple
autoantibodies and DRB1*04-DQA1*03:01-DQB1*03:02
compared with 06022 relatives with the same features.
Moreover, the frequency of dysglycemia was not influ-
enced by DR4-DQ8 or DR3 in 0602+ relatives. These
observations suggest that protection that is mediated
by DRB1*15:01-DQA1*01:02-DQB1*06:02 most often
overcomes HLA-encoded susceptibility on the other
chromosome.
Table 7—Frequencies of HLA haplotypes in 0602+ and 06022 relatives
Haplotypes or genotypes
0602+ 06022 0602+ 06022
All AAb+ Single AAb at screening and on follow-up
n/N % n/N % P n/N % n/N % P
DRB1*03+, (DRB1*042) 57/155 36.8 725/2,447 29.6 0.07 48/117 41.0 440/1,261 34.9 0.19
DRB1*03:01-DQA1*05:01-DQB1*
02:01+, (DRB1*042) 54/155 34.8 720/2,447 29.4 0.18 45/117 38.5 437/1,261 34.7 0.41
DRB1*04+, (DRB1*032) 54/155 34.8 1,339/2,447 54.7 ,0.0001 35/117 29.9 528/1,261 41.9 0.01
DRB1*04-DQA1*03:01-DQB1*
03:02+, (DRB1*032) 45/155 29.0 1,136/2,447 46.4 ,0.0001 29/117 24.8 445/1,261 35.3 0.02
DRB1*04+ and DRB1*03+ 0/155 0.0 755/3,203 23.6 ,0.0001 0/117 0.0 268/1,477 18.1 ,0.0001
DRB1*04-DQA1*03:01-DQB1*03:02+
and DRB1*03:01-DQA1*05:01-
DQB1*02:01+ 0/155 0.0 659/3,203 20.6 ,0.0001 0/117 0.0 216/1,477 14.6 ,0.0001
Single AAb at screening → multiple AAb Multiple AAb at screening
n/N % n/N % P n/N % n/N % P
DRB1*03+, (DRB1*042) 4/14 28.6 79/309 25.6 0.76 5/24 20.8 206/973 21.2 1.0
DRB1*03:01-DQA1*05:01-DQB1*
02:01+, (DRB1*042) 4/14 28.6 78/309 25.2 0.75 5/24 20.8 205/973 21.1 1.0
DRB1*04+, (DRB1*032) 7/14 50.0 188/309 60.8 0.41 12/24 50.0 623/973 64.0 0.19
DRB1*04-DQA1*03:01-DQB1*03:02+,
(DRB1*032) 6/14 42.9 165/309 53.4 0.58 10/24 41.7 526/973 54.1 0.3
DRB1*04+ and DRB1*03+ 0/14 0.0 115/413 27.8 0.01 0/24 0.0 373/1,313 28.4 0.0007
DRB1*04-DQA1*03:01-DQB1*03:02+
and DRB1*03:01-DQA1*05:01-
DQB1*02:01+ 0/14 0.0 104/413 25.2 0.02 0/24 0.0 339/1,313 25.8 0.001
1116 HLA Protection Inhibits T1D at Multiple Stages Diabetes Volume 65, April 2016
However, protection is not absolute. A small minority
of the 0602+ relatives had multiple autoantibodies or
hyperglycemic OGTTs at baseline or during follow-up, and
four relatives progressed to diabetes. Of these relatives,
three had at least two autoantibodies and all carried
predisposing HLA haplotypes on the other chromosome.
Although limited by the small numbers of subjects avail-
able for analysis, 0602+ relatives with multiple autoanti-
bodies have higher T1D risk compared with those with a
single autoantibody, but this is estimated to be about 50%
lower than the risk in 06022 relatives with multiple au-
toantibodies. Future studies could investigate whether
these relatives have DRB1*15:01-DQA1*01:02-DQB1*06:02
with mutations or alleles that weaken the protective ef-
fect. For example, we previously reported that DRB1*15:01-
DQA1*01:02-DQB1*06:02 haplotypes carrying allele 15 at
the microsatellite D6S265 (109 kb centromeric of HLA-A)
confer reduced protection from T1D; this effect was ob-
served in patients from Sweden who tended to develop
disease at an older age (37). It should also be noted that
among the 0602+ relatives who developed T1D in our
study, the one with single GADA positivity was much older
than most PTP participants.
In general, the 0602+ relatives were older and had
greater BMI values than the 06022 relatives and included
higher proportions of parents and lower proportions of
siblings. However, as an older age and a higher BMI are
likely outcomes of the protective effect of DRB1*15:01-
DQA1*01:02-DQB1*06:02 from disease progression, we
chose not to perform adjustments for them in our anal-
yses. These are not true confounders but rather direct
outcomes of the protective effect from T1D development.
By being protected from T1D, 0602+ relatives maintain-
ing autoantibody positivity over time are likely to be iden-
tified at an older age, with associated higher BMI values.
Consistent with this, 0602+ relatives with autoantibodies
were more often parents rather than siblings of T1D
probands. Schisterman et al. (38) elegantly described how
unnecessary adjustments could bias results; in this case,
adjusting for age and BMI would be an unnecessary adjust-
ment that would misleadingly diminish the impact of
DRB1*15:01-DQA1*01:02-DQB1*06:02 positivity. None-
theless, we analyzed siblings separately and showed that
even among them, DRB1*15:01-DQA1*01:02-DQB1*06:02
protects from the acquisition of multiple autoantibodies.
The protective effect of DRB1*15:01-DQA1*01:02-
DQB1*06:02 may result from interference with the immu-
nologically mediated pathogenesis of T1D. We show that
DRB1*15:01-DQA1*01:02-DQB1*06:02 markedly reduces
the likelihood of autoantibody development and the spread-
ing of autoimmune responses as determined by the number
of autoantibodies. In addition, it diminishes the likelihood
and the progression of glucose abnormalities, such as dys-
glycemia, and ultimately inhibits progression to T1D. Given
the function of antigen-presenting HLA molecules, the DR
or DQ molecules encoded by the protective haplotype may
influence the presentation of islet cell autoantigen epitopes,
a mechanism that could be operative in both the thymus
and peripheral lymphoid tissues, where tolerogenic presen-
tation of self-molecules, including T1D autoantigens, has
been shown (39). Thus, potential mechanisms of protection
include thymic deletion of autoreactive T cells (40), the
induction of regulatory T cells, or the induction of less
inflammatory responses. Models of affinity, competition,
and determinant capture are consistent with these mecha-
nisms and have been proposed to explain the genetic pro-
tection from HLA molecules (41,42). For example, the
heterodimer encoded by DQA1*01:02-DQB1*06:02 displays
high stability and increased ability to bind diabetogenic
self-epitopes compared with predisposing molecules (43–
46). These mechanisms, and ultimately whether certain
HLA molecules protect from T1D or increase risk, may
also be linked to variation in the density of expression of
HLA-DQ molecules on the cell surface. Reports indicate
that T1D-protective HLA-DQ molecules (including the
DQ molecule encoded by DQA1*01:02-DQB1*06:02) are
more stable than predisposing ones, and this may lead to
more sustained tolerogenic presentation of islet autoantigen
peptides (47).
In closing, DRB1*15:01-DQA1*01:02-DQB1*06:02 re-
duces the risk of developing autoantibodies, progressing
from single to multiple autoantibodies, and developing
dysglycemia and ultimately protects from overt diabetes.
This recognition has implications for the design of re-
cruitment strategies for prevention trials relevant to
each of the stages of disease progression recently pro-
posed (48), from genetic predisposition to the triggering
of autoimmunity, the spreading of the autoimmune re-
sponse, the development of dysglycemia, and later clinical
disease. A treatment that mimics or replicates the protec-
tion afforded by DRB1*15:01-DQA1*01:02-DQB1*06:02
might delay or prevent T1D at any of these stages.
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